Key Takeaways
- • Armistice Capital and two executives face jury trial for alleged pump-and-dump scheme involving $250 million in Vaxart stock during the COVID-19 pandemic, with closing arguments completed as of April 27, 2026.
- • Investors' counsel characterized the defendants' conduct as pandemic-era "greed," claiming misleading press releases artificially inflated stock value before a coordinated sell-off, while defense counsel maintains all Vaxart announcements were "true and accurate."
- • The case centers on the use of press releases as the primary mechanism for alleged market manipulation, raising questions about disclosure standards and executive accountability during volatile pandemic-era biotech trading.
Summary
A California federal jury is set to decide whether Armistice Capital and two of its executives engaged in a coordinated pump-and-dump scheme involving approximately $250 million in Vaxart stock. Closing arguments in the case were presented on Monday, April 27, 2026, with investors' counsel alleging that the defendants exploited pandemic-era market conditions through deliberate misrepresentation.
According to the plaintiffs' narrative, Armistice Capital and the two executives leveraged misleading press releases to artificially inflate Vaxart's stock price before executing a large-scale exit. Investors' counsel framed the conduct as pandemic-era "greed," suggesting a calculated exploitation of heightened retail investor interest and volatility in biotech equities during the COVID-19 crisis. The $250 million value underscores the material scale of the alleged scheme and potential investor losses at stake.
The defense maintains a contrasting position, with Armistice Capital's legal team arguing that all public announcements attributed to Vaxart were factually accurate and properly disclosed. This fundamental disagreement over the truthfulness and materiality of the company's press releases forms the core dispute for jury determination. The case highlights ongoing tensions between hedge funds' trading strategies and disclosure obligations, particularly during periods of elevated market speculation.
The jury's verdict will carry implications for hedge fund liability standards, the enforceability of press release disclosures in securities litigation, and investor protection frameworks during volatile market environments. The outcome may also establish precedent regarding executive accountability when financial institutions coordinate large equity positions alongside corporate announcements.
According to the plaintiffs' narrative, Armistice Capital and the two executives leveraged misleading press releases to artificially inflate Vaxart's stock price before executing a large-scale exit. Investors' counsel framed the conduct as pandemic-era "greed," suggesting a calculated exploitation of heightened retail investor interest and volatility in biotech equities during the COVID-19 crisis. The $250 million value underscores the material scale of the alleged scheme and potential investor losses at stake.
The defense maintains a contrasting position, with Armistice Capital's legal team arguing that all public announcements attributed to Vaxart were factually accurate and properly disclosed. This fundamental disagreement over the truthfulness and materiality of the company's press releases forms the core dispute for jury determination. The case highlights ongoing tensions between hedge funds' trading strategies and disclosure obligations, particularly during periods of elevated market speculation.
The jury's verdict will carry implications for hedge fund liability standards, the enforceability of press release disclosures in securities litigation, and investor protection frameworks during volatile market environments. The outcome may also establish precedent regarding executive accountability when financial institutions coordinate large equity positions alongside corporate announcements.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.